Amarin: A Physician's Perspective On Vascepa [View article]
DoctorX, as you are a physician, I would be very interested in your point by point analysis of today's Amarin article on SA by Alex Heisenberg. Specifically the medical issues he raises. Thanks.
Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. [View news story]
fully agree with comments .. Amarin has an excellent future.. but curious as to why FDA would put off NCE decsion... odd
AMRN.. "its value is based on the speculation that Vascepa will sell very well" really? The superior efficacy, safety and and utility of this drug and well documented from multiple sources .. where is the speculation in that? Are your articles some sort of community college homework assignment?
Amarin: A Physician's Perspective On Vascepa [View article]
Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made. [View news story]
Hot Biotechs And Possible Shorting Opportunities [View article]
6 Gilded Stocks To Avoid [View article]